Response to Casarett et al. (doi: 10.1089/jpm.2018.0658): Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms

Abstract

Get full access to this article

View all access options for this article.

References

Casarett

, Beliveau

, Arbus

: Benefit of tetrahydrocannabinol versus cannabidiol for common palliative care symptoms. J Palliat Med, 2019 [Epub ahead of print; DOI: 10.1089/jpm.2018.0658.]

Saadeh

, Rustem

: Medical marijuana use in a community cancer center. J Oncol Pract, 2018; 14:e566–e578.

Tanco

, Dumlao

, Kreis

, et al.: Attitudes and beliefs about medical usefulness and legalization of marijuana among cancer patients in a legalized and a nonlegalized state. J Palliat Med, 2019 [Epub ahead of print; DOI: 10.1089/jpm.2019.0218.]

Steele

, Ameson

, Zylla

: A comprehensive review of cannabis in patients with cancer: Availability in the USA, general efficacy, and safety. Curr Oncol Rep, 2019; 21:10.

Foster

, Abramovici

, Harris

: Cannabis and cannabinoids: Kinetics and interactions. Am J Med, 2019 [Epub ahead of print]; DOI: 10.1016/j.amjmed.2019.05.017.